(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
The most effective method to Guarantee Thorough Inclusion in Senior Protection. - 2Which One Energizes You the Most These Tech Developments
- 3Europe: 4 Urban communities for a Paramount Social Experience
- 4At least 171 measles cases confirmed in 9 states, CDC data shows
- 5Discussion on deployment of foreign troops ongoing, two sources tell 'Post'
- Which camera do you believe is great for first-time clients? !
- Doritos and Cheetos debut 'NKD' options, without artificial colors or flavors
- Tatiana Schlossberg, a granddaughter of JFK, is dead at 35 after cancer diagnosis
- The Job of a Land Legal counselor in Property Exchanges
- Watch Rocket Lab launch Japanese technology-demonstrating satellite to orbit tonight
- How food assistance programs can feed families and nourish their dignity
- REWE launches seventh Pick&Go test store in Hanover
- Yes, NASA's launching Artemis 2 astronauts to the moon on April Fools' Day. It's not a joke.
- An Extended period of Voyaging Carefully: the World with Reason
